Stoke Therapeutics, Inc.
NASDAQ:STOKBiotechnology
-$0.34 today
- Market cap
- $1.75B
- Beta
- 1.19
- P/E (TTM)
- -11.1
- EPS (TTM)
- -$2.69
Volume 0.76M
Average 0.64M
STOK Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Stoke Therapeutics, Inc.NASDAQ: STOK
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $1.05M rose 119.5% year over year, ahead of the +69.2% change in trailing-twelve-month depreciation & amortization. Sequentially, it fell 0.8% from the prior quarter. Over 3 fiscal years it compounded at +4.6% a year.
Context
- Depreciation & amortization amounted to 1.0% of revenue in FY2025, down 5.0 pp from a year earlier.
- Depreciation & amortization increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +119.5% holds above the trailing-twelve-month pace of +69.2%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 1.77M USD
- Year-over-year change
- -18.7%
- 4-year CAGR
- +16.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 1.77M | -18.7% |
| FY2024 | 2024-12-31 | 2.18M | -11.8% |
| FY2023 | 2023-12-31 | 2.47M | +59.7% |
| FY2022 | 2022-12-31 | 1.55M | +58.7% |
| FY2021 | 2021-12-31 | 974K | — |
Depreciation & Amortization vs competitors
How STOK compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +69.2% is the highest of 6, against a peer median of +1.3%.
- Depreciation & amortization amounts to 11.0% of revenue for STOK, versus a peer median of 14.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $22.24M USD | +1.2% | +16.4% | 14.3% | |
| LTM Sep 2026 | $21.89M USD | +6.2% | +0.9% | 2.3% | |
| LTM Mar 2026 | $8.99M USD | +4.0% | -4.3% | 12.5% | |
| LTM Mar 2026 | $3.54M USD | +69.2% | +4.6% | 11.0% | |
| LTM Mar 2026 | €2.72M EUR | -0.9% | +1.0% | 20.3% | |
| LTM Mar 2026 | $620K USD | +1.3% | +10.1% | — | |
| LTM Mar 2026 | $577.79K USD | — | +4.5% | 62.7% | |
| Peer median (excluding STOK) | — | +1.3% | +2.8% | 14.3% | |
Competitors are the stored peer set for STOK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 12.41M | 8.78M | 36.56M | 184.42M |
| Cost of Revenue | 0 | 0 | 0 | 0 | 0 |
| Gross Profit | 0 | 12.41M | 8.78M | 36.56M | 184.42M |
| Gross Margin | — | 100.0% | 100.0% | 100.0% | 100.0% |
| Research & Development | 54.17M | 77.84M | 82.23M | 89.13M | 137.92M |
| Selling, General & Admin | 31.9M | 38.92M | 41.32M | 48.79M | 67.09M |
| Operating Expenses | 86.07M | 116.76M | 123.55M | 137.93M | 205.01M |
| Depreciation & Amortization | 974K | 1.55M | 2.47M | 2.18M | 1.77M |
| EBITDA | (84.83M) | (99.52M) | (102.23M) | (86.8M) | (5.12M) |
| EBITDA Margin | — | -802.3% | -1164.4% | -237.5% | -2.8% |
| Operating Income | (86.07M) | (104.36M) | (114.77M) | (101.37M) | (20.59M) |
| Operating Margin | — | -841.2% | -1307.2% | -277.3% | -11.2% |
| Interest Income | 120K | 3.12M | 9.91M | 12.64M | 13.77M |
| Interest Expense | 0 | 0 | 0 | 0 | 9K |
| Other Income / Expenses | 260K | 3.29M | 10.07M | 12.39M | 13.71M |
| Income Before Tax | (85.81M) | (101.07M) | (104.7M) | (88.98M) | (6.89M) |
| Pre-Tax Margin | — | -814.7% | -1192.5% | -243.4% | -3.7% |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (85.81M) | (101.07M) | (104.7M) | (88.98M) | (6.89M) |
| Net Margin | — | -814.7% | -1192.5% | -243.4% | -3.7% |
| EPS (Basic) | (2.34) | (2.60) | (2.38) | (1.65) | (0.12) |
| EPS (Diluted) | (2.34) | (2.60) | (2.38) | (1.65) | (0.12) |
| Weighted Avg Shares | 36.74M | 38.9M | 43.99M | 54.01M | 59.22M |
| Weighted Avg Shares (Diluted) | 36.74M | 38.9M | 43.99M | 54.01M | 59.22M |
Stoke Therapeutics, Inc.
NASDAQ:STOK
Intrinsic Alpha fair value
Locked
Current Price
$26.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.